Purple Biotech Ltd (PPBT) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Purple Biotech Ltd (PPBT) has a cash flow conversion efficiency ratio of -0.033x as of September 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (ILA-1.07 Million ≈ $-2.86K USD) by net assets (ILA32.81 Million ≈ $87.98K USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. See net asset quality index of Purple Biotech Ltd to measure how much of total assets are equity-financed.
Purple Biotech Ltd - Cash Flow Conversion Efficiency Trend (2017–2024)
This chart illustrates how Purple Biotech Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore PPBT strategic capital deployment ratio to see how much of total assets are deployed in long-term investments.
Purple Biotech Ltd Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Purple Biotech Ltd ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
PVW Resources Ltd
AU:PVW
|
-1.696x |
|
CARLSON INV. ZY 13
F:2HB
|
-0.001x |
|
Sumber Mas Konstruksi Tbk PT
JK:SMKM
|
-0.018x |
|
NCC Group plc
LSE:NCC
|
0.124x |
|
Minco Capital Corp
V:MMM
|
0.009x |
|
KC Property PLC
BK:KC
|
-0.185x |
|
BTU Metals Corp
V:BTU
|
-0.025x |
|
Eversafe Rubber Bhd
KLSE:0190
|
0.000x |
Annual Cash Flow Conversion Efficiency for Purple Biotech Ltd (2017–2024)
The table below shows the annual cash flow conversion efficiency of Purple Biotech Ltd from 2017 to 2024. For the full company profile with market capitalisation and key ratios, see PPBT market cap overview.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | ILA32.91 Million ≈ $88.23K |
ILA-14.37 Million ≈ $-38.52K |
-0.437x | +24.86% |
| 2023-12-31 | ILA34.30 Million ≈ $91.95K |
ILA-19.93 Million ≈ $-53.42K |
-0.581x | -63.50% |
| 2022-12-31 | ILA47.10 Million ≈ $126.27K |
ILA-16.73 Million ≈ $-44.87K |
-0.355x | -51.69% |
| 2021-12-31 | ILA65.11 Million ≈ $174.55K |
ILA-15.25 Million ≈ $-40.89K |
-0.234x | -54.50% |
| 2020-12-31 | ILA79.75 Million ≈ $213.81K |
ILA-12.09 Million ≈ $-32.42K |
-0.152x | +70.50% |
| 2019-12-31 | ILA10.86 Million ≈ $29.11K |
ILA-5.58 Million ≈ $-14.96K |
-0.514x | +33.31% |
| 2018-12-31 | ILA11.00 Million ≈ $29.50K |
ILA-8.48 Million ≈ $-22.73K |
-0.771x | +23.24% |
| 2017-12-31 | ILA8.59 Million ≈ $23.04K |
ILA-8.63 Million ≈ $-23.13K |
-1.004x | -- |
About Purple Biotech Ltd
Purple Biotech Ltd., a clinical-stage company, focuses on developing therapies to overcome tumor immune evasion and drug resistance for cancer patients in the United States. Its oncology pipeline includes CM24, a humanized monoclonal antibody that blocks the interactions of carcinoembryonic antigen related cell adhesion molecule 1 as a combination therapy with anti-PD-1 checkpoint inhibitors, whi… Read more